NeurosofTech Competitors

The NeuroLeadership Institute is a leading global research organization and pioneer in the neuroscience of leadership. Since its inception the Institute has united the world’s foremost neuroscientists, leadership researchers, and organizational practitioners with the purpose of transforming how we think, develop, and perform. With operations worldwide, the Institute provides unique brain-based, process-focused, and outcome-driven methodologies and frameworks that help individuals and organizations facilitate positive change and lead more effectively. Organized into three branches, the NeuroLeadership Institute provides a customized approach to applied neuroscience. Our Research department highlights breakthroughs in neuroscience and produces peer-reviewed research that is published in papers comprising the NeuroLeadership Journal. We feature these papers at our annual Summit. Our Education department offers programs for individuals and teams that wish to learn new skills and explore the four domains of neuroleadership: decision making and problem solving, emotional regulation, collaboration, and the facilitation of change. Our Solutions business operationalizes our research to help organizations transform their effectiveness, with a focus in three practice areas: Performance, Diversity, and Learning.

Cerebral is a mental health company dedicated to improving access to treatment for anxiety and depression. We offer ongoing video visits with a prescribing provider, medication & medication delivery if prescribed, and an assigned care manager who is available for regular check-in calls and unlimited messaging.

BrainScope is a leading neurotechnology company advancing brain health through objective, AI-powered insights derived from brain electrical activity (EEG). Its proprietary platform analyzes EEG data from any source using advanced machine and deep learning to deliver rapid, radiation-free, accessible and cost-effective biomarkers - greatly expanding the clinical utility of traditional EEG. BrainScope's device for head injury assessment was the first device in neurology cleared by the FDA under the AI/Machine Learning-Enabled Medical Device category. BrainScope has commercialized its first set of FDA-cleared biomarkers for mild brain injury assessment (both brain bleeds and concussions) with remarkable outcomes in major U.S. health systems, which include ~50% reduction in unnecessary head CTs, substantial reductions in patient length of stay in emergency departments, and high utility for concussion clinics, personal injury cases and sports. The company is now advancing novel biomarkers for early Alzheimer’s detection, ARIA assessment, rapid stroke evaluation, concussion subtyping, military blast exposure, and others.